Shopping Cart 0
Cart Subtotal
USD 0

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Overview 7

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Companies Involved in Therapeutics Development 19

Addex Therapeutics Ltd 19

Bristol-Myers Squibb Company 20

Denovo Biopharma LLC 20

Domain Therapeutics SA 21

Eli Lilly and Company 21

Johnson & Johnson 22

Merck & Co Inc 22

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Drug Profiles 23

ADX-92639-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BMT-133218-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DT-2442-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

JNJ-40411813-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

JNJ-5515-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

LSN-2535717-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LY-2607540-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LY-2969822-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

LY-3020371-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

LY-341495-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

pomaglumetad methionil-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Dormant Products 40

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Discontinued Products 42

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Product Development Milestones 43

Featured News & Press Releases 43

Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia 43

Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43

Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 44

Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44

Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 45

Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 46

Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47

Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 49

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 49

Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 50

Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 50

Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 52

Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 52

Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Addex Therapeutics Ltd, H2 2017 19

Pipeline by Bristol-Myers Squibb Company, H2 2017 20

Pipeline by Denovo Biopharma LLC, H2 2017 20

Pipeline by Domain Therapeutics SA, H2 2017 21

Pipeline by Eli Lilly and Company, H2 2017 21

Pipeline by Johnson & Johnson, H2 2017 22

Pipeline by Merck & Co Inc, H2 2017 22

Dormant Products, H2 2017 40

Dormant Products, H2 2017 (Contd..1), H2 2017 41

Discontinued Products, H2 2017 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment


Companies

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Overview 7

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Companies Involved in Therapeutics Development 19

Addex Therapeutics Ltd 19

Bristol-Myers Squibb Company 20

Denovo Biopharma LLC 20

Domain Therapeutics SA 21

Eli Lilly and Company 21

Johnson & Johnson 22

Merck & Co Inc 22

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Drug Profiles 23

ADX-92639-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BMT-133218-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DT-2442-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

JNJ-40411813-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

JNJ-5515-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

LSN-2535717-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LY-2607540-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LY-2969822-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

LY-3020371-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

LY-341495-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

pomaglumetad methionil-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Dormant Products 40

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Discontinued Products 42

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Product Development Milestones 43

Featured News & Press Releases 43

Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia 43

Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43

Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 44

Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44

Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 45

Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 46

Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47

Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 49

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 49

Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 50

Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 50

Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 52

Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 52

Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Addex Therapeutics Ltd, H2 2017 19

Pipeline by Bristol-Myers Squibb Company, H2 2017 20

Pipeline by Denovo Biopharma LLC, H2 2017 20

Pipeline by Domain Therapeutics SA, H2 2017 21

Pipeline by Eli Lilly and Company, H2 2017 21

Pipeline by Johnson & Johnson, H2 2017 22

Pipeline by Merck & Co Inc, H2 2017 22

Dormant Products, H2 2017 40

Dormant Products, H2 2017 (Contd..1), H2 2017 41

Discontinued Products, H2 2017 42

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment


Companies

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment